Intracoronary Transplantation of Mesenchymal Stem Cells with Overexpressed Integrin-Linked Kinase Improves Cardiac Function in Porcine Myocardial Infarction
Dan Mu,Xin-Lin Zhang,Jun Xie,Hui-Hua Yuan,Kun Wang,Wei Huang,Guan-Nan Li,Jian-Rong Lu,Li-Juan Mao,Lian Wang,Le Cheng,Xiao-Li Mai,Jun Yang,Chuan-Shuai Tian,Li-Na Kang,Rong Gu,Bin Zhu,Biao Xu
DOI: https://doi.org/10.1038/srep19155
IF: 4.6
2016-01-01
Scientific Reports
Abstract:The effect of mesenchymal stem cell (MSCs)-based therapy on treating acute myocardial infarction (MI) is limited due to poor engraftment and limited regenerative potential. Here we engineered MSCs with integrin-linked kinase (ILK), a pleiotropic protein critically regulating cell survival, proliferation, differentiation and angiogenesis. We firstly combined ferumoxytol with poly-L-lysine (PLL) and found this combination promisingly enabled MRI visualization of MSCs in vitro and in vivo with good safety. We provided visually direct evidence that intracoronary ILK-MSCs had substantially enhanced homing capacity to infarct myocardium in porcine following cardiac catheterization induced MI. Intracoronary transplantation of allogeneic ILK-MSCs, but not vector-MSCs, significantly enhanced global left ventricular ejection fraction (LVEF) by 7.8% compared with baseline, by 10.3% compared with vehicles and inhibited myocardial remodeling compared with vehicles at 15-day follow-up. Compared with vector-MSCs, ILK-MSCs significantly improved regional LV contractile function, reduced scar size, fibrosis, cell apoptosis and increased regional myocardial perfusion and cell proliferation. This preclinical study indicates that ILK-engineered MSCs might promote the clinical translation of MSC-based therapy in post-MI patients and provides evidence that ferumoxytol labeling of cells combined with PLL is feasible in in vivo cell tracking.